JNJJohnson & Johnson

Johnson & Johnson1 (NYSE: JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases. Johnson & Johnson will collaborate with Sail to advance its lead immune-mediated disease...

GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving plan.

Key PointsEli Lilly currently displays stronger upward momentum in top-line growth, whereas Johnson & Johnson maintains a higher but flatter overall baseline...

Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking records while also lifting their outlooks.

AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.

Covista (NYSE: CVSA), America's largest healthcare educator, today announced the appointments of Emily C. Chiu and Leslie Storms to its Board of Directors, effective August 17, 2026. Ms. Chiu and Ms. Storms join the Covista Board at an important moment as Covista embarks on Purpose at Scale, its...

These are the stocks posting the largest moves in early trading...

Johnson & Johnson said Monday it would pay an estimated $5.5 billion to resolve lawsuits alleging its baby powder and other talc products cause ovarian cancer...

U.S. stock futures were mixed on Tuesday, as the Dow Jones index gained but the S&P 500 and Nasdaq 100 indices declined.read more...